信达生物上半年“毛利率”达86%,“玛仕度肽”成重要增长引擎

动脉网
Sep 14, 2025

信达生物2025年上半年业绩亮眼,毛利率高达86%,营收和净利润分别增长至59.53亿元和12.13亿元。玛仕度肽作为全球首个GCG/GLP-1双靶点减重药物,上市后迅速脱销,预计2025年和2026年销售额将分别达到6亿元和18亿元。此外,PD-1抑制剂信迪利单抗在激烈竞争中保持领先地位,销售额约38.19亿元,占公司收入的46%。贝伐珠单抗和利妥昔单抗等生物类似药及代理产品也表现出色。高毛利率...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10